{"id":"https://genegraph.clinicalgenome.org/r/a7436d60-3e98-4f05-94d4-0aedfb223d46v1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between *TK2* and primary mitochondrial disease was evaluated using the ClinGen Clinical Validity Framework as of September 6, 2023. The *TK2* gene encodes mitochondrial thymidine kinase 2, a mitochondrial deoxyribonucleoside kinase that phosphorylates thymidine, deoxycytidine, and deoxyuridine. Defects of this protein lead to impaired synthesis of mtDNA precursors leading to mtDNA depletion.\n\nThe *TK2* gene was first reported in relation to autosomal recessive primary mitochondrial disease in 2001 (PMID 11687801), in individuals with infantile onset severe myopathy. While various names have been given to the constellation of features seen in those with *TK2*-related disease, pathogenic variants in this gene cause a primary mitochondrial disease. Therefore, the *TK2* phenotype has been lumped into one disease entity according to the ClinGen Lumping and Splitting Framework.\n\nEvidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included 11 unique variants (six missense, two frameshift, three stop-gained variants) from three publications (PMIDs: 11687801, 16908738, 29602790) although there are over 100 cases reported in the medical literature. Age of onset varies from infancy to adulthood and outcomes range from death in infancy to being alive in adulthood at the time of report. Features seen in affected individuals include myopathy (muscle weakness that leads to respiratory failure in some), seizures, dysarthria, dysphagia, respiratory insufficiency, ophthalmoplegia, and sensorineural hearing loss. Muscle biopsies show mitochondrial DNA depletion and combined mitochondrial respiratory chain enzyme deficiencies. The mechanism of disease appears to be loss of function. \n\nThis gene-disease relationship is also supported by its known biochemical function, knockout mouse model, and knock-in mouse model with a variant found in a patient showing ataxic, progressive muscle weakness and TK2 deficiency phenotype (PMIDs: 33340416, 15639197, 18467430, 20123860). \n\nIn summary, there is definitive evidence to support this gene-disease relationship, including that more than three years have elapsed since the first proposal of the association. This relationship has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. No convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on September 6, 2023 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/a7436d60-3e98-4f05-94d4-0aedfb223d46","GCISnapshot":"https://genegraph.clinicalgenome.org/r/0f1bc80d-2f35-4e45-ba17-a2ba34ee51de","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/0f1bc80d-2f35-4e45-ba17-a2ba34ee51de_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2023-09-06T04:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/0f1bc80d-2f35-4e45-ba17-a2ba34ee51de_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2024-01-22T16:27:33.191Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f1bc80d-2f35-4e45-ba17-a2ba34ee51de_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f1bc80d-2f35-4e45-ba17-a2ba34ee51de_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/27af9c4a-dc3c-411c-9276-0089cf16fd2e","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3a8290b7-44fb-43fe-bc64-fb0be4ce29cc","type":"Finding","dc:description":"Despite appearing normal at birth, the TK2−/− mice rapidly display an ataxic phenotype after 10–12 days of life, with severely impaired motor coordination and gait, and abnormal limb-clasping reflexes indicative of an underlying neuropathology. Severe reductions in mtDNA levels (∼50%) were observed throughout the brain of P7 TK2−/− mice falling to more severe reductions (∼70%) by P12 in all brain regions examined. The study showed that this loss of mtDNA copy is associated with reduced expression of mtDNA-encoded ETC subunits in the cerebellum, hippocampus and cortex by P7, corresponding to the onset of neurological impairment. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20123860","rdfs:label":"TK2 knockout mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/9dc610b5-e379-46a9-a303-1172ec67ab9c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ac8d48b-d525-4bd4-a008-09406f153947","type":"Finding","dc:description":"Severe TK2 deficiency, followed by myopathy.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18467430","rdfs:label":"H126N knock-in mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/0f1bc80d-2f35-4e45-ba17-a2ba34ee51de_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d6e8810-5394-4f6f-86ca-226467d9d863","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6e5b219-cfe1-4532-b12b-ef99edad682c","type":"FunctionalAlteration","dc:description":"The two point mutations affected the Km values for all three types of substrate; dThd, dCyd, and ATP/MgCl2. When the enzymes were assayed in the presence of excess ATP, the T108M mutant had 6-fold higher Km values for dThd and dCyd and 15-fold lower Vmax values for dThd and dCyd as compared to wild-type TK2 (wt TK2) (Table 3). The R192K mutant of TK2 also had higher Km values and lower Vmax values with both substrates, and the efficiencies were about two percent of the wild-type enzyme (Table 3).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15639197","rdfs:label":"Enzyme activity using recombinant DNA"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0f1bc80d-2f35-4e45-ba17-a2ba34ee51de_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e7612584-ba02-42ba-86b0-bf54759791c6","type":"EvidenceLine","dc:description":"Many other gene products with similar function.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d218ce8-5d27-48a6-9ea6-9e6f78f7cf11","type":"Finding","dc:description":"mtDNA maintenance","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33340416","rdfs:label":"mtDNA maintenance","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/0f1bc80d-2f35-4e45-ba17-a2ba34ee51de_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ea3b1cf-48ff-401d-be6b-7036ba428332_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d4f3483-c05b-4a0f-b1c4-9ce898e2d7f5","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d4f3483-c05b-4a0f-b1c4-9ce898e2d7f5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","allele":{"id":"https://genegraph.clinicalgenome.org/r/87775b16-0ea2-433a-955e-817b23c1c7c0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.582G>T (p.Lys194Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA396187709"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/1630d37a-3378-46fb-b1ab-756f0d6aa501","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1630d37a-3378-46fb-b1ab-756f0d6aa501_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","allele":{"id":"https://genegraph.clinicalgenome.org/r/7fceb565-fd8c-4f45-b3c1-9238048893ef","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.103C>T (p.Gln35Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10603421"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4ea3b1cf-48ff-401d-be6b-7036ba428332","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","rdfs:label":"88","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":72,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/87775b16-0ea2-433a-955e-817b23c1c7c0"},{"id":"https://genegraph.clinicalgenome.org/r/7fceb565-fd8c-4f45-b3c1-9238048893ef"}],"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/1630d37a-3378-46fb-b1ab-756f0d6aa501_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/4d4f3483-c05b-4a0f-b1c4-9ce898e2d7f5_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/bf9939f1-f9ce-4a05-b467-34a1811ab9d3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59cf0a68-a343-4264-a81e-098770c58ab5","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59cf0a68-a343-4264-a81e-098770c58ab5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16908738","allele":{"id":"https://genegraph.clinicalgenome.org/r/584fe7fe-44f5-4280-9b0c-2c47c0e37231","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.373C>T (p.Gln125Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343305"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/55a26dfe-311e-4600-88a2-da47216ad090","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/55a26dfe-311e-4600-88a2-da47216ad090_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Muscle biopsy specimens were compatible with mitochondrial myopathy. There were multiple ragged red fibers and cytochrome-c oxidase–negative fibers (Figure, A), which had increased staining for succinate dehydrogenase (ragged blue fibers, Figure, B).\n\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/55a26dfe-311e-4600-88a2-da47216ad090_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16908738","allele":{"id":"https://genegraph.clinicalgenome.org/r/08213b44-b645-40e3-ad08-3af32b786728","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.323C>T (p.Thr108Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA324292"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bf9939f1-f9ce-4a05-b467-34a1811ab9d3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16908738","rdfs:label":"4","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":7,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/584fe7fe-44f5-4280-9b0c-2c47c0e37231"},{"id":"https://genegraph.clinicalgenome.org/r/08213b44-b645-40e3-ad08-3af32b786728"}],"firstTestingMethod":"Genotyping","previousTesting":false,"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/59cf0a68-a343-4264-a81e-098770c58ab5_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/55a26dfe-311e-4600-88a2-da47216ad090_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/dbf5794c-5a71-4186-b954-21ff95da062a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d789c07b-a41b-4428-ab72-6dea3c3bf5c5","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d789c07b-a41b-4428-ab72-6dea3c3bf5c5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In muscle mitochondria, the activity of the variant TK2 with deoxythymidine (dThd) as the substrate was reduced to 45%, of the mean control value in patients 1.With deoxycytidine (dCyt) as the substrate, the activity of TK2 was reduced to 32% in patient 1.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d789c07b-a41b-4428-ab72-6dea3c3bf5c5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11687801","allele":{"id":"https://genegraph.clinicalgenome.org/r/e99c5a9e-ad71-44da-981c-abd9d05d03da","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.361C>A (p.His121Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA320611"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/dbf5794c-5a71-4186-b954-21ff95da062a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11687801","rdfs:label":"1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":24,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e99c5a9e-ad71-44da-981c-abd9d05d03da"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Genotyping","previousTesting":true,"previousTestingDescription":"No mutations in the 22 mitochondrial transfer RNA genes of the muscle DNA.","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d789c07b-a41b-4428-ab72-6dea3c3bf5c5_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/01cca550-c711-4325-9084-3ad785631a5c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/275e342f-e657-46a5-a618-a3573553994b","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/275e342f-e657-46a5-a618-a3573553994b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","allele":{"id":"https://genegraph.clinicalgenome.org/r/584fe7fe-44f5-4280-9b0c-2c47c0e37231"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/08033520-1bf8-4c3d-b87b-872ae5e47ed7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/08033520-1bf8-4c3d-b87b-872ae5e47ed7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"TK2 deficiency","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/08033520-1bf8-4c3d-b87b-872ae5e47ed7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","allele":{"id":"https://genegraph.clinicalgenome.org/r/a7dfce92-5ccf-4dd3-a214-0f1e87d979f2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.395T>C (p.Met132Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA396189973"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/01cca550-c711-4325-9084-3ad785631a5c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","rdfs:label":"33","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":10,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/a7dfce92-5ccf-4dd3-a214-0f1e87d979f2"},{"id":"https://genegraph.clinicalgenome.org/r/584fe7fe-44f5-4280-9b0c-2c47c0e37231"}],"firstTestingMethod":"Exome sequencing","previousTesting":false,"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/275e342f-e657-46a5-a618-a3573553994b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/08033520-1bf8-4c3d-b87b-872ae5e47ed7_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/dd16a539-07b0-4fa1-b4d9-0af91a24daf6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7b87cfd-d00c-47be-809e-be86bfc6a2d8","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7b87cfd-d00c-47be-809e-be86bfc6a2d8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","allele":{"id":"https://genegraph.clinicalgenome.org/r/6a486623-1c80-4480-9aea-c8f8d0f5d7ad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.604_606del (p.Lys202del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA343316"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/dd16a539-07b0-4fa1-b4d9-0af91a24daf6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","rdfs:label":"90","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":35,"allele":{"id":"https://genegraph.clinicalgenome.org/r/6a486623-1c80-4480-9aea-c8f8d0f5d7ad"},"firstTestingMethod":"Exome sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d7b87cfd-d00c-47be-809e-be86bfc6a2d8_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/d9448e3b-1a67-45a1-af46-9d949bc881b9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bdd1a27c-15a4-4565-a522-f90ae90f291f","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bdd1a27c-15a4-4565-a522-f90ae90f291f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","allele":{"id":"https://genegraph.clinicalgenome.org/r/aef8a93c-509e-413c-9dbf-331531d883ba","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.144_145del (p.Lys50fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/972912"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ef2a5f7d-bf9f-400e-9c4a-3cd5c3f2950a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef2a5f7d-bf9f-400e-9c4a-3cd5c3f2950a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Catalytic activity was 2-4% of wild-type activity,","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ef2a5f7d-bf9f-400e-9c4a-3cd5c3f2950a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","allele":{"id":"https://genegraph.clinicalgenome.org/r/08213b44-b645-40e3-ad08-3af32b786728"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d9448e3b-1a67-45a1-af46-9d949bc881b9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29602790","rdfs:label":"35","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/aef8a93c-509e-413c-9dbf-331531d883ba"},{"id":"https://genegraph.clinicalgenome.org/r/08213b44-b645-40e3-ad08-3af32b786728"}],"firstTestingMethod":"Exome sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/bdd1a27c-15a4-4565-a522-f90ae90f291f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/ef2a5f7d-bf9f-400e-9c4a-3cd5c3f2950a_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/bb92c5d3-0017-41f0-8de0-5e7289ffe5ea_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a1c3087-59cd-43cd-a813-d64c77d0df86","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a1c3087-59cd-43cd-a813-d64c77d0df86_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The functional consequence was studied in muscle mitochondria. The activity of the variant TK2 with deoxythymidine (dThd) as the substrate was reduced to 14% and with deoxycytidine (dCyt) as the substrate, the activity of TK2 was reduced to 13%. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2a1c3087-59cd-43cd-a813-d64c77d0df86_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11687801","allele":{"id":"https://genegraph.clinicalgenome.org/r/97062225-7a5a-4c5b-94ea-8b7d409472e1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004614.5(TK2):c.635T>A (p.Ile212Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA341231"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/bb92c5d3-0017-41f0-8de0-5e7289ffe5ea","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11687801","rdfs:label":"2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":8,"allele":{"id":"https://genegraph.clinicalgenome.org/r/97062225-7a5a-4c5b-94ea-8b7d409472e1"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Genotyping","previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/2a1c3087-59cd-43cd-a813-d64c77d0df86_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":7617,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/P87EJTUQd20","type":"GeneValidityProposition","disease":"obo:MONDO_0044970","gene":"hgnc:11831","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_0f1bc80d-2f35-4e45-ba17-a2ba34ee51de-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}